PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
ANNAPOLIS, Md., Sept. 3, 2013
ANNAPOLIS, Md., Sept. 3, 2013 /PRNewswire/ --PharmAthene, Inc. (NYSE MKT:
PIP), a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that Eric I. Richman,
President and Chief Executive Officer will present at the Rodman & Renshaw
Annual Global Investment Conference on Monday, September 9, 2013 at 10:25 a.m.
EDT in Room 7.03, 7^th Floor of the Millennium Broadway Hotel, New York.
Event: Rodman & Renshaw Annual Global Investment Conference
Date: Monday, September 9, 2013
Place: Millennium Broadway Hotel, New York, NY
Time: 10:25 am EDT
PharmAthene was formed to meet the critical needs of the United States and its
allies by developing and commercializing medical countermeasures against
biological and chemical threats. PharmAthene's current biodefense portfolio
includes the following product candidates:
oSparVax^® - a next generation recombinant protective antigen (rPA) anthrax
oRecombinant BChE - a novel bioscavenger for the prevention and treatment
of morbidity associated with exposure to chemical nerve agents
oValortim^® - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
In addition, in May 2013, the Delaware Supreme Court issued its ruling on the
appeal in our litigation with SIGA Technologies, affirming the Court of
Chancery's finding that SIGA was liable for breach of contract, reversing its
finding of promissory estoppel, and remanding the case back to the Court of
Chancery to reconsider the appropriate remedy and award of attorney's fees and
expert witness costs in light of the Supreme Court's opinion. For more
information about PharmAthene, please visit www.PharmAthene.com.
SOURCE PharmAthene, Inc.
Contact: Stacey Jurchison, PharmAthene, Inc., (410) 269-2610,
Press spacebar to pause and continue. Press esc to stop.